<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00028535</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-01407</org_study_id>
    <secondary_id>1999C0326</secondary_id>
    <secondary_id>OSU-0167</secondary_id>
    <secondary_id>NCI-84</secondary_id>
    <secondary_id>OSU-99H0326</secondary_id>
    <secondary_id>CDR0000069102</secondary_id>
    <secondary_id>U01CA076576</secondary_id>
    <nct_id>NCT00028535</nct_id>
  </id_info>
  <brief_title>Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid Tumors</brief_title>
  <official_title>Phase I Trial of Interleukin-12 in Combination With Paclitaxel Plus Herceptin in Patients With Her2-positive Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      Phase I trial to study the effectiveness of interleukin-12, paclitaxel, and trastuzumab in&#xD;
      treating patients who have solid tumors. Interleukin-12 may kill tumor cells by stopping&#xD;
      blood flow to the tumor and by stimulating a person's white blood cells to kill cancer cells.&#xD;
      Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop&#xD;
      growing or die. Monoclonal antibodies such as trastuzumab can locate tumor cells and either&#xD;
      kill them or deliver tumor-killing substances to them without harming normal cells. Combining&#xD;
      interleukin-12, chemotherapy, and monoclonal antibody therapy may kill more tumor cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      I. Determine the maximum tolerated dose of interleukin-12 when given in combination with&#xD;
      paclitaxel and trastuzumab (Herceptin速) in patients with HER2/neu-overexpressing&#xD;
      malignancies.&#xD;
&#xD;
      II. Determine the response rate and time to progression in patients treated with this&#xD;
      regimen.&#xD;
&#xD;
      III. Determine the anti-tumor effect of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of interleukin-12.&#xD;
&#xD;
      Patients receive trastuzumab (Herceptin速) IV over 30-90 minutes on days 1, 8, and 15 and&#xD;
      paclitaxel IV over 3 hours on day 1 of course 1. Beginning with course 2, patients receive&#xD;
      trastuzumab and paclitaxel as in course 1 and interleukin-12 subcutaneously on days 2, 5, 9,&#xD;
      12, 16, and 19. Courses repeat every 21 days for up to 1 year in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of interleukin-12 until the maximum&#xD;
      tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2&#xD;
      of 3 or 2 of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
      Patients are followed every 3 months for 1 year and then every 6 months thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2001</start_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MTD of IL-12, defined as the dose level one level beneath that dose at which 2 or more of 6 patients showed DLT, based on the NCI CTC version 2.0</measure>
    <time_frame>Up to 21 days</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Male Breast Cancer</condition>
  <condition>Recurrent Breast Cancer</condition>
  <condition>Recurrent Endometrial Carcinoma</condition>
  <condition>Recurrent Gastric Cancer</condition>
  <condition>Recurrent Non-small Cell Lung Cancer</condition>
  <condition>Recurrent Ovarian Epithelial Cancer</condition>
  <condition>Recurrent Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive trastuzumab (Herceptin速) IV over 30-90 minutes on days 1, 8, and 15 and paclitaxel IV over 3 hours on day 1 of course 1. Beginning with course 2, patients receive trastuzumab and paclitaxel as in course 1 and interleukin-12 subcutaneously on days 2, 5, 9, 12, 16, and 19. Courses repeat every 21 days for up to 1 year in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>trastuzumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>anti-c-erB-2</other_name>
    <other_name>Herceptin</other_name>
    <other_name>MOAB HER2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>Anzatax</other_name>
    <other_name>Asotax</other_name>
    <other_name>TAX</other_name>
    <other_name>Taxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>recombinant interleukin-12</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>cytotoxic lymphocyte maturation factor</other_name>
    <other_name>IL-12</other_name>
    <other_name>interleukin-12</other_name>
    <other_name>natural killer cell stimulatory factor</other_name>
    <other_name>Ro 24-7472</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed HER2/neu-overexpressing (2+ or 3+) malignancy by any&#xD;
             standardized assay (fluorescence in-situ hybridization allowed)&#xD;
&#xD;
          -  Measurable or evaluable disease&#xD;
&#xD;
          -  Failed standard curative therapy&#xD;
&#xD;
          -  No brain or CNS metastasis&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Not specified&#xD;
&#xD;
          -  Male or female&#xD;
&#xD;
          -  Performance status - Karnofsky 70-100%&#xD;
&#xD;
          -  At least 6 months&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 8 g/dL (transfusion or epoetin alfa allowed)&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST and ALT no greater than 3.0 times ULN&#xD;
&#xD;
          -  Hepatitis B surface antigen negative&#xD;
&#xD;
          -  Creatinine no greater than 1.5 times ULN&#xD;
&#xD;
          -  Calcium no greater than 11 mg/dL (calcium-lowering agents allowed)&#xD;
&#xD;
          -  No active or unstable cardiovascular disease&#xD;
&#xD;
          -  No cardiac disease requiring drug or device intervention&#xD;
&#xD;
          -  No coronary artery disease&#xD;
&#xD;
          -  No congestive heart failure&#xD;
&#xD;
          -  Cardiac ejection fraction normal by echocardiogram or MUGA scan&#xD;
&#xD;
          -  No significant peripheral neuropathy&#xD;
&#xD;
          -  No significant CNS disease&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No serious concurrent infection requiring IV antibiotic therapy&#xD;
&#xD;
          -  No clinically significant autoimmune disease (e.g., rheumatoid arthritis)&#xD;
&#xD;
          -  No clinically significant gastrointestinal bleeding&#xD;
&#xD;
          -  No uncontrolled peptic ulcer disease&#xD;
&#xD;
          -  No inflammatory bowel disease&#xD;
&#xD;
          -  No other major illness that would preclude study participation&#xD;
&#xD;
          -  No other concurrent malignancy except non-melanoma skin cancer or carcinoma in situ of&#xD;
             the cervix&#xD;
&#xD;
          -  No prior interleukin-12&#xD;
&#xD;
          -  No prior trastuzumab (Herceptin速)&#xD;
&#xD;
          -  At least 3 weeks since prior chemotherapy&#xD;
&#xD;
          -  At least 3 weeks since prior hormonal therapy&#xD;
&#xD;
          -  No concurrent systemic corticosteroids&#xD;
&#xD;
          -  At least 3 weeks since prior radiotherapy&#xD;
&#xD;
          -  At least 3 weeks since prior surgery&#xD;
&#xD;
          -  At least 3 weeks since prior investigational drug&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Carson</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>January 4, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>June 3, 2013</last_update_submitted>
  <last_update_submitted_qc>June 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
    <mesh_term>Endometrial Neoplasms</mesh_term>
    <mesh_term>Breast Neoplasms, Male</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Interleukin-12</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

